Non-Small Cell Lung Cancer Market Size and Share : Global Industry Expansion Strategies, Future Growth, Emerging Demands, Opportunity Assessment and Demand Forecast by 2033


 A recently published study by FMI expects the global Non-Small Cell Lung Cancer Market to augment at a 7.2% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 20 Billion is expected for the market. From 2018 to 2022, the industry experienced noteworthy growth, registering a value CAGR of 6.7% and closing at US$ 10 Billion. The expansion of the non-small cell lung cancer market may be attributed to an increase in cancer cases as well as increased patient knowledge about their health.

Non-small cell lung cancer, one of the most common kinds of lung cancer, reduces the lungs' ability to provide oxygen to the blood. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide. The causes are passive smoking, active smoking, consuming polluted water, and being exposed to air pollution. It can, however, be treated with a variety of medicines such as immunotherapy, targeted therapy, and others.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16143

The two primary causes of non-small cell lung cancer are excessive tobacco intake and active participation in passive smoking. Long-term air pollution exposure promotes the development of non-small cell lung cancer. However, the existence of large firms, as well as the entry of new essential players, will result in excessive market rivalry. This will decrease the rate of expansion of the lung cancer treatments market.

The high expense of therapy or treatment will limit the scope of expansion even further. Because of the prevalence of advanced healthcare infrastructure, greater research and development capabilities by pharmaceutical firms, and quick adoption of new and better healthcare technology, North America leads the non-small cell lung cancer market. Asia-Pacific, on the other hand, is expected to have the greatest growth rate throughout the projection period due to increased healthcare infrastructure spending, increasing prevalence of non-small cell lung cancer, and a growing senior population sensitive to cancer.

Key Takeaways from the Market Study

  • FMI projects the global non-small cell lung cancer market to expand at a 7.2% value CAGR by 2033
  • The global non-small cell lung cancer market is estimated at a market value of US$ 10 Billion
  • The global non-small cell lung cancer market is expected to garner a market value of US$ 20 Billion
  • North America is forecast to be the most lucrative for non-small cell lung cancer market growth.
  • As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.7% during the assessment period 2023-2033.
  • Europe is expected to grow at a CAGR of 7% during the assessment period 2023-2033.
  • The chemotherapy segment is expected to hold the largest market share for non-small cell lung cancer in the forecast period 2023-2033.

“Rising investment in research & development efforts by the key players will fuel market expansion even more,” says an analyst at FMI

Market Competition

Key players in the non-small cell lung cancer market are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, and AbbVie.

Recent Developments:

  • In December 2022, Pluvicto®, a targeted radioligand treatment, has been authorised by the European Commission (EC), according to Novartis. Pluvicto® is licensed for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition (mCRPC). AR pathway inhibitor and taxane-based chemotherapy were used to treat these individuals.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the global non-small cell lung cancer mrket, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Cancer Type Squamous Cell Carcinoma, Adenocarcinoma and Large-cell Carcinoma, by Treatment (Chemotherapy, Targeted Therapy and Immunotherapy), across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Key Segments Profiled in the Non-Small Cell Lung Cancer Industry Survey

Non-Small Cell Lung Cancer Market by Cancer Type:

  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Large-cell Carcinoma

Non-Small Cell Lung Cancer Market by Treatment:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

Comments

Post a Comment

Popular posts from this blog

Beyond COVID-19: A Look at Vaccines Market Post-Pandemic From 2023 to 2033

Image
 In recent years, the Vaccines Market has undergone a dramatic transition brought on by ground-breaking scientific discoveries and the pressing need for universal immunisation. The COVID-19 pandemic acted as a stimulus for a surge in vaccine demand that has prompted academics and pharmaceutical corporations to develop at a previously unheard-of rate. This blog examines the changing market environment for vaccines, highlighting significant trends, difficulties, and opportunities. Technology advancements like mRNA and vector-based platforms have completely changed how vaccines are developed. These innovative techniques have proven to be remarkably effective against contagious illnesses like COVID-19, opening the door for the development of new vaccines. In response to the pandemic, mRNA vaccines were developed and distributed quickly, showcasing the promise of these ground-breaking technology. Supercharge Your Knowledge: Dive into the Booming Vaccines market with Our Sample Report @ ht
Read more

Key Players Shaping the 3D Cell Culture Market: By 2022 to 2031

Image
  The global 3D cell culture market is anticipated to account for a growth rate of around 9.8% over the forecast period from 2022 to 2031. The global market is expected to account for around US$ 1.15 Billion in 2022 and attain a valuation of US$ 2.67 Billion by 2031. According to the analysis done by Future Market Insights, the global 3D cell culture market accounted for a CAGR of 4.8% in 2021. During the historical period of 2016 to 2021, the 3D cell culture market expanded at a CAGR of 7.1%. According to the studies conducted by Future Market Insights, the comparative analysis along with the market growth rate of the global 3D cell culture market is expected to show a negative BPS growth in the H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, However, a positive BPS growth is expected in H1-2022 over H1- 2021 duration with 02 Basis Point Share (BPS). The global 3D cell culture market observes a drop in the BPS values owned to its disadvantage as compared to surface
Read more

Technological Advancements Fueling the Physiotherapy Equipment Market By 2023 to 2033

 The physical well-being and quality of life of people who are recuperating from injuries or who have chronic diseases are greatly enhanced by physical therapy. The Physiotherapy Equipment Market has experienced growth in tandem with the increase in demand for physiotherapy services. Due in large part to technological innovation, the prevalence of neurological and musculoskeletal illnesses is rising, and this sector of the economy is expanding quickly. The market for physiotherapy equipment has a large selection of gadgets and instruments made to help with the healing process. The industry has made considerable strides to meet a variety of treatment demands, from heat and cold therapy devices to electrotherapy machines and therapeutic exercise equipment. These contemporary resources help physiotherapists deliver more focused care, increase patient results, and enrich the therapeutic process as a whole. Grab Your Exclusive Report: Unveiling the Spectacular Growth of the Physiotherapy E
Read more